[
  {
    "ts": null,
    "headline": "These 3 Attractive Stocks Keep Cruising Higher",
    "summary": "Despite recent negativity, several stocks, including Verizon Communications, Gilead Sciences, and Alibaba, have shaken off the woes, showing stability and relative strength throughout the period.",
    "url": "https://finnhub.io/api/news?id=d61fceb7f03f611dc3b968fa152ec6d1ba377d420da7469e20cc87afb7aaf590",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741729620,
      "headline": "These 3 Attractive Stocks Keep Cruising Higher",
      "id": 133185365,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Despite recent negativity, several stocks, including Verizon Communications, Gilead Sciences, and Alibaba, have shaken off the woes, showing stability and relative strength throughout the period.",
      "url": "https://finnhub.io/api/news?id=d61fceb7f03f611dc3b968fa152ec6d1ba377d420da7469e20cc87afb7aaf590"
    }
  },
  {
    "ts": null,
    "headline": "Tracking Renaissance Technologies 13F Portfolio - Q4 2024 Update",
    "summary": "Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA. Read a portfolio update here.",
    "url": "https://finnhub.io/api/news?id=7ec5e1a10869fd2ac0edf332e5cc9731271a2844e308c8ff8479d01288fa561f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741728555,
      "headline": "Tracking Renaissance Technologies 13F Portfolio - Q4 2024 Update",
      "id": 133140400,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2164745052/image_2164745052.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA. Read a portfolio update here.",
      "url": "https://finnhub.io/api/news?id=7ec5e1a10869fd2ac0edf332e5cc9731271a2844e308c8ff8479d01288fa561f"
    }
  },
  {
    "ts": null,
    "headline": "First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet",
    "summary": "FOSTER CITY, Calif., March 11, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP). The data were presented during an oral abstract session at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) and were also published today in The",
    "url": "https://finnhub.io/api/news?id=bcd50b8ed47e9229cb10cfdd0d5f4df8ccaef14aca09c7bca782d63178f16c7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741714620,
      "headline": "First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet",
      "id": 133185366,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., March 11, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP). The data were presented during an oral abstract session at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) and were also published today in The",
      "url": "https://finnhub.io/api/news?id=bcd50b8ed47e9229cb10cfdd0d5f4df8ccaef14aca09c7bca782d63178f16c7d"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD) Leerink Partners Global Healthcare Conference - (Transcript)",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) Leerink Partners Global Healthcare Conference Call March 11, 2025 10:40 AM ETCompany ParticipantsCindy Perettie -...",
    "url": "https://finnhub.io/api/news?id=ef5c09d238447c271627bfe49d6df8ada7ba68917677fc1e207494de7a24802c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741702445,
      "headline": "Gilead Sciences, Inc. (GILD) Leerink Partners Global Healthcare Conference - (Transcript)",
      "id": 133136377,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) Leerink Partners Global Healthcare Conference Call March 11, 2025 10:40 AM ETCompany ParticipantsCindy Perettie -...",
      "url": "https://finnhub.io/api/news?id=ef5c09d238447c271627bfe49d6df8ada7ba68917677fc1e207494de7a24802c"
    }
  },
  {
    "ts": null,
    "headline": "These 10 stocks beating the market’s recent Trump slump have this in common",
    "summary": "These 10 stocks beating the market’s recent Trump slump have this in common",
    "url": "https://finnhub.io/api/news?id=e8383f6a57268bab0c9cf132cc1de00ab367c29c1676d860b3901c1a8d646442",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741700400,
      "headline": "These 10 stocks beating the market’s recent Trump slump have this in common",
      "id": 133136678,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "These 10 stocks beating the market’s recent Trump slump have this in common",
      "url": "https://finnhub.io/api/news?id=e8383f6a57268bab0c9cf132cc1de00ab367c29c1676d860b3901c1a8d646442"
    }
  },
  {
    "ts": null,
    "headline": "Buy 5 Non-Tech High-Flying Nasdaq Stocks Amid Index's Recent Bloodbath",
    "summary": "We have narrowed our search to five Nasdaq Composite-listed non-tech stocks that have provided double-digit returns year to date. These are: EXC, GILD, PAA, SRAD, CTAS.",
    "url": "https://finnhub.io/api/news?id=48ad993fb9f7f6e9a6f35d18632f239966d57578077327c7cbc5abe9266ec541",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741698720,
      "headline": "Buy 5 Non-Tech High-Flying Nasdaq Stocks Amid Index's Recent Bloodbath",
      "id": 133185367,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "We have narrowed our search to five Nasdaq Composite-listed non-tech stocks that have provided double-digit returns year to date. These are: EXC, GILD, PAA, SRAD, CTAS.",
      "url": "https://finnhub.io/api/news?id=48ad993fb9f7f6e9a6f35d18632f239966d57578077327c7cbc5abe9266ec541"
    }
  },
  {
    "ts": null,
    "headline": "BMEZ: Recession Fears Making You Sick? Buy This High-Yield Healthcare Fund",
    "summary": "BlackRock Health Sciences Term Trust is a top pick for high-yield dividends in healthcare. Click here to find out why BMEZ stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=0a90bbc72c21544b52437a24252fdcd27158f61d0b5128e17ea6b2ed0058f641",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741698125,
      "headline": "BMEZ: Recession Fears Making You Sick? Buy This High-Yield Healthcare Fund",
      "id": 133136036,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148098716/image_2148098716.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "BlackRock Health Sciences Term Trust is a top pick for high-yield dividends in healthcare. Click here to find out why BMEZ stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=0a90bbc72c21544b52437a24252fdcd27158f61d0b5128e17ea6b2ed0058f641"
    }
  },
  {
    "ts": null,
    "headline": "Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks",
    "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad Genetics (NASDAQ:MYGN).",
    "url": "https://finnhub.io/api/news?id=9fe4a725567f0ded1bfde5503ad24daef9853559a131d4fedf9568a7ea220327",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741683790,
      "headline": "Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks",
      "id": 133184494,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad Genetics (NASDAQ:MYGN).",
      "url": "https://finnhub.io/api/news?id=9fe4a725567f0ded1bfde5503ad24daef9853559a131d4fedf9568a7ea220327"
    }
  },
  {
    "ts": null,
    "headline": "The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI)",
    "summary": "In 2024, technology stocks involved in artificial intelligence (AI) led the Nasdaq-100 index higher, while healthcare stocks struggled due in part to concerns about how Robert F. Kennedy's nomination for Health and Human Services Secretary might impact the industry.  AppLovin (NASDAQ: APP) advanced 713%.  Palantir Technologies (NASDAQ: PLTR) advanced 340%.",
    "url": "https://finnhub.io/api/news?id=93b57b99b9cb9dcc4fc0ea2d744294bcfde18c7d9daca45653d1a68d93840d05",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741681200,
      "headline": "The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI)",
      "id": 133185369,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "In 2024, technology stocks involved in artificial intelligence (AI) led the Nasdaq-100 index higher, while healthcare stocks struggled due in part to concerns about how Robert F. Kennedy's nomination for Health and Human Services Secretary might impact the industry.  AppLovin (NASDAQ: APP) advanced 713%.  Palantir Technologies (NASDAQ: PLTR) advanced 340%.",
      "url": "https://finnhub.io/api/news?id=93b57b99b9cb9dcc4fc0ea2d744294bcfde18c7d9daca45653d1a68d93840d05"
    }
  }
]